http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 24 Feb 2026 02:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Press+Releases/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html <p align="center"><em>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu</em>®</p> <p align="center"><em>Clinical trial with AVA6103 is expected to be initiated in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, &quot;the Company&quot;, &quot;Avacta&quot;), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform&apos;s compared to a marketed antibody drug conjugate (ADC).</p> <p align="justify">The data analysis compares pre|CISION FAP-cleavable payload delivery http://www.streetinsider.com/Globe+Newswire/Avacta%26apos%3Bs+pre%7CCISION+Mechanism+for+Payload+Delivery+Shows+Key+Advantages+Compared+to+an+Antibody+Drug+Conjugate+in+Innovative+AI-Driven+Analysis/26045529.html Tue, 24 Feb 2026 02:00:00 -0500 A.50215078 AVCT O.00438411 O.01112127 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Press+Releases/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532 http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html <p align="center"><em>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026</em></p> <p align="justify">LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.</p> <p align="justify">The IND approval is an important http://www.streetinsider.com/Globe+Newswire/Avacta+Announces+U.S.+Food+and+Drug+Administration+Clearance+of+the+Investigational+New+Drug+%28IND%29+Application+for+the+Second+pre%7CCISION%C2%AE+Medicine%2C+FAP-Exatecan+%28AVA6103%29/25871587.html Wed, 21 Jan 2026 08:03:00 -0500 A.06822034 A.21849991 A.37422324 A.50215078 AVCT O.00438411 O.01112127 O.20026344 O.20331252 O.21095532